Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
250 participants
INTERVENTIONAL
2016-03-01
2029-03-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* In this study, family and medical history information is collected alongside a blood or saliva sample for genetic studies.
* Individuals with a past or present childhood thyroid cancer/nodule or a thyroid cancer suspected to be inherited in their family are invited to participate.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical and Genetic Studies in Familial Non-medullary Thyroid Cancer
NCT01109420
A Gene Hunting Study for Familial Papillary Thyroid Cancer
NCT02776969
Study of Molecular Pathways in Medullary Thyroid Carcinoma and Correlation of Molecular Data With Clinical Behavior of the MTC in Individuals Patients
NCT01424878
IDEntification of New Predisposition Genes in Differentiated THYroid Cancer
NCT05014698
Diagnosing Thyroid Cancer Using a Blood Test
NCT01586520
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The investigators would like to use the participant DNA to look for alterations in genes. The investigator will perform DNA sequencing and other genetic studies to identify errors in the genes that may contribute to the formation of thyroid nodules and cancer.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
SCREENING
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Lower Suspected Familial Predisposition
Lower Suspected Familial Predisposition
Screening and Enrollment:
Consent, Family HX, Medical HX, Blood/Saliva which will categorize by suspected hereditary predisposition: Based on family and medical history.
\- Sample stored in Biorepository
No interventions assigned to this group
Higher Suspected Familial Predisposition
Higher Suspected Familial Predisposition
Screening and Enrollment:
Consent, Family HX, Medical HX, Blood/Saliva which will categorize by suspected hereditary predisposition: Based on family and medical history.
\- Specimen Testing and Analysis
•Referral to Genetic Counselor, if indicated
•Referral to Genetic Counselor, if indicated
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
•Referral to Genetic Counselor, if indicated
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Individual adult patient with current or previous known or suspected thyroid cancer or nodule(s) if they come from a family with a high suspicion of hereditary cancer (as below).
* Individuals from families with a high suspicion of hereditary thyroid cancer:
* Families with a current or previous diagnosis of a thyroid cancer/nodule occurring in childhood (\<18 years old).
* Families with a high suspicion of hereditary thyroid cancer/nodules other than above to include:
* Families with thyroid cancer in multiple individuals
* Families with thyroid cancer and a known genetic syndrome
* Families with thyroid cancer and a suspected genetic syndrome (e.g. multiple childhood cancers in the family, multiple primary cancers, multiple endocrinopathies, etc.)
Exclusion Criteria
* Individuals who are unable to complete study materials.
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dana-Farber Cancer Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Junne Kamihara, MD
MD, PhD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Junne Kamihara, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Dana-Farber Cancer Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Junne Kamihara, MD, PhD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
15-159
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.